Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

Vos, Hanne; Lambein, Kathleen; Richard, François; Mariën, Bram; Nevelsteen, Ines; Punie, Kevin; Wildiers, Hans; Berben, Lieze; Laenen, Annouschka; Floris, Giuseppe; Desmedt, Christine; Smeets, Ann

doi:10.1038/s41523-021-00332-7

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of gemcitabine and the partial T-HIFU restricted tumor growth, but only minimal changes in intratumoral CTL were The immune phenotypes are adapted from [43] for melanoma, NSCLC, TNBC, RCC, PDAC, and CRC-MSS. HER2 + BC is reported to have a similar phenotype to TNBC [167,168]. The immune phenotypes are determined through TIL infiltration proportions and immune transcriptome profiling in neuroblastoma [169], glioma [170], gene expression data from the Cancer Genome Atlas for OC [171], and TIL infiltration for CRC-MSI [46,172] and HCC [173].…”

Section: Ablative Fus + Icimentioning

confidence: 99%

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Jahangiri,

2024

Pharmaceutics

View full text Add to dashboard Cite

Despite spectacular clinical successes across several cancer types, immune checkpoint inhibition is effective only in subgroups of patients and suffers from significant systemic toxicities, highlighting the need to understand and locally overcome the mechanisms of therapeutic resistance. Similarly to other therapeutics, immunotherapies face delivery challenges (for example, antibodies need to reach their targets) and immunological barriers that are unique to solid tumors and their microenvironment. Interestingly, focused ultrasound (FUS), with or without microbubbles, which has been shown to enhance gene and drug delivery, notably in oncology, has been recently found to trigger immunological responses. In recent years, there has been a strong emphasis on understanding the biological and immunological effects of FUS for cancer therapy, and FUS is now emerging as an approach that can improve cancer immunotherapy. We herein review: (1) the immunological barriers implicated in ICI resistance; (2) the fundamentals of FUS +/− MB and the current knowledge on leveraging FUS +/− MB bioeffects for improving ICI therapy efficacy; (3) the immune profile of tumor models that have been successfully treated with FUS and ICI; and finally, (4) we discuss the challenges ahead for translating FUS and MB treatments to the clinic, highlighting the exciting perspectives for this new research area.

show abstract

Section: Ablative Fus + Icimentioning

confidence: 99%

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Jahangiri,

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The genomic evolution of breast cancer during metastasis has been well elucidated, however, the evolution of immune cells and the tumor microenvironment is less understood. Breast cancer tumor immune microenvironment (TIME) studies have primarily focused on primary tumors [ 27 , 28 , 29 ]. In early-stage breast cancer, a positive correlation between longer survival and greater tumor infiltration lymphocyte (TIL) count, as well as upregulation of immune-related gene expression, has been observed [ 30 , 31 ].…”

Section: Breast Tumor Immune Microenvironmentmentioning

confidence: 99%

The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets

Yang

Lü

Weisenberger

et al. 2022

Genes

View full text Add to dashboard Cite

Breast cancer (BC) mortality is almost exclusively due to metastasis, which is the least understood aspect of cancer biology and represents a significant clinical challenge. Although we have witnessed tremendous advancements in the treatment for metastatic breast cancer (mBC), treatment resistance inevitably occurs in most patients. Recently, efforts in characterizing mBC revealed distinctive genomic, epigenomic and transcriptomic (multi-omic) landscapes to that of the primary tumor. Understanding of the molecular underpinnings of mBC is key to understanding resistance to therapy and the development of novel treatment options. This review summarizes the differential molecular landscapes of BC and mBC, provides insights into the genomic heterogeneity of mBC and highlights the therapeutically relevant, multi-omic features that may serve as novel therapeutic targets for mBC patients.

show abstract

Prognostic value and microenvironmental crosstalk of exosome-related signatures in human epidermal growth factor receptor 2 positive breast cancer

Zhao,

Shen,

et al. 2024

Open Life Sciences

View full text Add to dashboard Cite

This study aimed to determine the prognostic value and microenvironmental crosstalk of exosome-related signatures in human epidermal growth factor receptor 2 positive breast cancer (HER2+ BC). Transcriptome sequencing and clinicopathological data were downloaded from the Cancer Genome Atlas. The 10X single cell sequencing dataset was downloaded from the National Center for Biotechnology Information Gene Expression Omnibus. Exosomes-Related Genes were extracted from the ExoCarta and Gene Set Enrichment Analysis databases. FGF9, SF3B4, and EPCAM were found and deemed the most accurate predictive signatures. Patients with HER2+ BC were subtyped into three groupings by exosome prognostic gene (EPGs). The expression of SF3B4 was positively linked with the infiltration of macrophages, neutrophils, and CD4+ T cells. The expression characteristics of EPGs were associated with the biological process of “response to xenobiotic stimuli.” Interactions were relatively high between malignant epithelial cells and fibroblasts, endothelial cells, monocytes, and macrophages. Malignant epithelial cells interact more with fibroblasts and endothelial cells. The migration inhibitory factor pathway was the primary outgoing signaling pattern, while the C-C motif chemokine ligand pathway was the primary incoming signaling pattern for communication between malignant epithelial cells and macrophages. This study described the role of exosome signatures in the prognosis and microenvironment of HER2+ BC and provided a basis for future research.

show abstract

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

Cited by 3 publications

References 24 publications

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors

The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets

Prognostic value and microenvironmental crosstalk of exosome-related signatures in human epidermal growth factor receptor 2 positive breast cancer

Contact Info

Product

Resources

About